Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Nov 1 - Nov 6
KD is an efficient treatment for pediatric drug-resistant epilepsy (DRE)
Biomedicines 11, 2538
The heavier the patient, the more likely they are to accumulate such conditions
Failure of initial multimodal therapy to achieve adequate weight loss may necessitate adjunctive treatment with medications or bariatric surgery, both of which present patient-specific risks and limitations
In the SUSTAIN clinical trial program evaluating subcutaneous semaglutide for type 2 diabetes, once-weekly dosing (0.5 mg or 1.0 mg) reduced HbA1c by 1.5% to 1.8% from baseline, with superior glycemic control compared to specific comparators in head-to-head trials (SUSTAIN-7 vs dulaglutide
US$ 28.66
US$ 22.53
US$ 20.02
